PharmAla Biotech and LaNeo MDMA Supply
TORONTO – PharmAla Biotech Holdings Inc. is thrilled to announce its role as a supplier of LaNeo™ MDMA for a clinical trial at Harvard Medical School's esteemed Maclean Hospital, recognized as one of the largest centers for psychiatric and neuroscientific research globally.
With the growing interest in psychedelics for therapeutic applications, PharmAla's commitment to providing high-quality MDMA is poised to support groundbreaking research. "We have been receiving numerous inquiries from prominent research entities about clinical trials involving MDMA, and we are pleased to play a part in advancing these studies," shared Nicholas Kadysh, CEO of PharmAla.
Advancing Clinical Research
PharmAla aims to facilitate the research community by simplifying access to its products. Researchers can now utilize a novel platform that offers critical information and insights into drug quality directly from the company’s website. This initiative highlights PharmAla’s dedication to excellence and responsiveness to the needs of its partners.
Supporting U.S. Trials
The management team at PharmAla is actively exploring opportunities to establish a more efficient supply chain model within the US for upcoming trials. This strategic move is expected to enhance the logistics of delivering their MDMA products to researchers without compromising on quality or timelines.
Participation in Global Conferences
PharmAla is also set to attend the prestigious CPHI conference in Milan, bringing together leaders and potential partners in the pharmaceutical space from around the world. This event presents an excellent avenue for PharmAla to connect with prospective distribution partners, which is crucial for its expansion in the European market.
Strengthening Partnerships
"Our discussions with potential partners across Europe have been promising. The CPHI conference provides us the perfect platform to reinforce those relationships while exploring new avenues for collaboration," stated Dr. Shane Morris, COO of PharmAla Biotech.
About PharmAla Biotech Holdings Inc.
PharmAla is not only focused on supplying MDMA but is also at the forefront of research involving MDXX class molecules. Its dual mission aims to address the clinical demand for generic, clinical-grade MDMA and to innovate within the psychedelic drug space. As one of the few companies permitted to provide clinical-grade MDMA outside of trials, PharmAla is committed to maintaining stringent relationships with regulators to ensure compliance and safety.
The Future of Psychedelic Research
PharmAla's ongoing research and development has led to the establishment of various intellectual property families, including ALA-002, highlighting its position as a leader in the industry. With a focus on clinical efficacy and safety, PharmAla continues to pave the way for new therapeutic methods in psychiatry and beyond.
For further inquiries, PharmAla can be reached at:
Nicholas Kadysh
Chief Executive Officer
Email: press@PharmAla.ca
Phone: 1-855-444-6362
Frequently Asked Questions
1. What is PharmAla’s role in the Harvard trial?
PharmAla Biotech is the supplier of LaNeo MDMA for a clinical trial at Harvard's Maclean Hospital.
2. What other initiatives is PharmAla involved in?
In addition to supplying MDMA, PharmAla is participating in the CPHI conference to establish distribution partnerships.
3. Why is LaNeo MDMA significant?
LaNeo MDMA represents a clinical-grade option for researchers exploring therapeutic applications in psychiatry and neuroscience.
4. How does PharmAla ensure product quality?
PharmAla provides a platform where researchers can access drug product quality information directly, ensuring transparency and trust.
5. What is PharmAla’s vision for the future?
The company aims to alleviate clinical-grade MDMA shortages and advance innovation in psychedelics for therapeutic use.
